{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-042444","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.718007+00:00","generated_at":"2026-06-02T02:43:41.538964+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Estrella Immunopharma amends clinical trial service agreement with Eureka to clarify termination payment terms","bullets":["Amendment No. 1 to SOW #001 for EB103 anti-CD19 ARTEMIS® clinical trial clarifies pay-on-termination obligations.","Upon termination, Estrella pays only for achieved milestones, pass-through costs, and third-party commitments before notice.","Eureka must use commercially reasonable efforts to cancel or reduce such third-party commitments.","Amendment effective March 4, 2024; filed on May 13, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-042444","json":"https://secwatch.observer/filing/0001213900-24-042444.json","markdown":"https://secwatch.observer/filing/0001213900-24-042444.md","text":"https://secwatch.observer/filing/0001213900-24-042444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024042444/0001213900-24-042444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024042444/ea0205983-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:43:41.538964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cdd9575a8728d0f51a82b5b093d288b399b73ac","claim":"Estrella Immunopharma, Inc. amended Amendment No. 1 to the Statement of Work with Eureka Therapeutics, Inc. (effective 2024-03-04).","evidence_excerpt":"On May 13, 2024, Estrella Immunopharma, Inc. (the “Company”), Estrella Biopharma, Inc. (“Estrella”), a wholly-owned subsidiary of the Company and the sole operating subsidiary of the Company, and Eureka Therapeutics, Inc. (“Eureka”), the controlling shareholder of the Company, entered into Amendment No. 1 to the Statement of Work (“Amendment No. 1”), effective as of March 4, 2024, which amends Statement of Work #001 (the “SOW”), dated and effective as of March 4, 2024, among the Company, Estrella, and Eureka, relating to the services (“Services”) to be performed by Eureka for Estrella in connection with Estrella’s EB103 anti-CD19 ARTEMIS® clinical trial.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024042444/0001213900-24-042444-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Eureka Therapeutics, Inc."},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}